Brief: Immuneering Announces First Patient Dosed In Its Phase 1/2A Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF, RAS Mutations
27/03/2024 12:18
March 27 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE
1/2A
TRIAL OF IMM-6-415 TO TREAT ADVANCED SOLID TUMORS WITH RAF OR
RAS MUTATIONS
* IMMUNEERING CORP - INITIAL PK, PD AND SAFETY DATA EXPECTED
IN
2024
Source text for Eikon: ID:nGNXcqDvF
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences